Retatrutide
Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors. By engaging three metabolic pathways, it represents the next generation of weight management therapies with the potential for greater efficacy in both weight loss and metabolic improvement.
Concentration
10 mg/mL
Duration
Approx. 10-60 weeks depending on vial size and titration
Key Benefits
Related Peptides
Peptide TherapyAOD-9604
Weight management peptide focused on fat metabolism support
$295+
Peptide TherapyMOTS-c
Metabolic efficiency and energy utilization peptide
$325+
Peptide Therapy5-Amino-1MQ
Metabolic support peptide for body composition and wellness optimization
$165+
Peptide TherapyTirzepatide
Tirzepatide is a dual GIP/GLP-1 receptor agonist that targets two incretin pathways simultaneously. It has demonstrated significant efficacy in clinical weight loss trials and offers enhanced metabolic benefits compared to single-receptor therapies.
$199+
Prescription therapies require medical evaluation and supervision. Results vary. Side effects and risks are discussed during consultation.